Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Burkitt Lymphoma 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × IL32 protein, human × Clear all
NCT02809092 2019-10-15

Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

Hospital de Clinicas de Porto Alegre

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00303667 2017-12-28

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 1/2 Completed
50 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡